STING inhibition alleviates experimental peritoneal damage: potential therapeutic relevance for peritoneal dialysis
The Journal of Pathology · 2025-10 · 267 (2) · 196-212
DOI: 10.1002/path.6462 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, online erschienen am 14.08.2025. Verfasst von Vanessa Marchant und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Health Research Institute-Fundación Jiménez Díaz University Hospital, Univ…. Hauptthemen laut MEDLINE: Peritoneal Dialysis, Membrane Proteins, Peritoneum. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Comunidad Autónoma de Madrid, Instituto de Salud Carlos III, European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia.
Abstract (Originalsprache)
Peritoneal dialysis (PD) is a widely used kidney replacement therapy for patients with end‐stage kidney disease. Nevertheless, long‐term exposure to PD fluid can damage the peritoneal membrane, leading to ultrafiltration failure and, ultimately, discontinuation of PD. Investigation of the molecular mechanisms underlying this damage is essential for identifying new therapeutic targets to mitigate peritoneal deterioration in PD patients. To this end, we employed RNA sequencing in a preclinical model of peritoneal injury, induced by prolonged chlorhexidine (CHX) exposure, which revealed cytosolic DNA‐sensing signaling as a novel pathway. Next, we demonstrated that key players in this pathway, such as the stimulator of interferon genes (STING) and its downstream signaling effectors (interferon regulatory factor 3, interferon‐stimulated genes, and nuclear factor‐κB signaling), were upregulated in experimental peritoneal damage. Moreover, increased STING expression was observed in human peritoneal biopsies from patients with PD. Subsequent studies in STING‐deficient mice showed reduced proinflammatory gene expression and immune cell infiltration, together with inhibited nuclear factor‐κB pathway activation at both early (10 days) and late (30 days) stages of CHX‐induced peritoneal injury. STING deficiency also reduced peritoneal membrane thickening, fibrosis, and mesothelial‐to‐mesenchymal transition (MMT)‐related changes in advanced CHX‐induced damage. Furthermore, pharmacological inhibition of STING with C‐176 attenuated CHX‐induced peritoneal inflammation. Macrophages were identified as one of the STING‐expressing cell types in the injured peritoneum. Hence, in vitro STING blockade in activated macrophages inhibited MMT in cultured mesothelial cells, suggesting that STING activation in this population may drive peritoneal fibrosis. Additionally, STING deficiency reduced peritoneal inflammation in S. epidermidis ‐induced peritonitis and decreased adhesion scores in a postsurgical intra‐abdominal adhesion model. These findings identify STING as a pivotal mediator of peritoneal injury and support its potential as a novel therapeutic target to prevent PD‐associated ultrafiltration failure. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
- RICORS2040, Madrid, Spain.
- Laboratory of Nephrology and Hypertension, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
- Tissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa (CBM), CSIC - Universidad Autónoma de Madrid, Madrid, Spain.
- Premium Research, S.L., Guadalajara, Spain.
- IMDEA Food Institute, Universidad Autónoma de Madrid, Madrid, Spain.
ORCID-Profile: Vanessa Marchant, Sandra Rayego-Mateos, Manuel López-Cabrera, Adrián M Ramos, Marta Ruiz-Ortega
Förderung
- Comunidad Autónoma de Madrid
- Instituto de Salud Carlos III
- European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia
- Marie Skłodowska-Curie
- Comunidad de Madrid
Zitieren
APA
Marchant, V., García-Giménez, J., González-Mateo, G. T., Sandoval, P., Tejedor-Santamaria, L., Rayego-Mateos, S., Ramos, R., Jiménez-Heffernan, J. A., Ortiz, A., Raby, A. C., López-Cabrera, M., Ramos, A. M., & Ruiz-Ortega, M. (2025). STING inhibition alleviates experimental peritoneal damage: potential therapeutic relevance for peritoneal dialysis. The Journal of Pathology, 267(2), 196-212. https://doi.org/10.1002/path.6462
Vancouver
Marchant V, García-Giménez J, González-Mateo GT, Sandoval P, Tejedor-Santamaria L, Rayego-Mateos S, et al. STING inhibition alleviates experimental peritoneal damage: potential therapeutic relevance for peritoneal dialysis. The Journal of Pathology. 2025;267(2):196-212. doi:10.1002/path.6462
BibTeX
@article{Marchant2025,
author = {Marchant, Vanessa and García-Giménez, Jorge and González-Mateo, Guadalupe T and Sandoval, Pilar and Tejedor-Santamaria, Lucía and Rayego-Mateos, Sandra and Ramos, Ricardo and Jiménez-Heffernan, José A and Ortiz, Alberto and Raby, Anne-Catherine and López-Cabrera, Manuel and Ramos, Adrián M and Ruiz-Ortega, Marta},
title = {STING inhibition alleviates experimental peritoneal damage: potential therapeutic relevance for peritoneal dialysis},
journal = {The Journal of Pathology},
year = {2025},
volume = {267},
number = {2},
pages = {196--212},
doi = {10.1002/path.6462}
}
EUVIMED